论文部分内容阅读
目的:探讨系统性红斑狼疮血清可溶性DcR3(Decoy receptor3)水平表达及与治疗药物的关系。方法:收集SLE患者51例,健康对照组19例,用酶联免疫吸附试验(ELISA)检测血清可溶性DcR3浓度,采用SLE疾病活动指数(SLEDAI)评判SLE疾病活动性,分析SLE治疗方案中主要用药(泼尼松、环磷酰胺、硫唑嘌呤、羟氯喹、白芍总苷)与血清可溶性DcR3浓度及SLEDAI的关系。结果:SLE患者血清可溶性DcR3浓度显著高于正常对照组(t=2.42,P<0.05),而且与SLEDAI积分呈正相关(r=0.373,P<0.01),SLE治疗方案中使用泼尼松组DcR3浓度比未使用组显著升高(P<0.05),而使用羟氯喹组却显著降低,此外使用泼尼松、环磷酰胺组比不使用组有较高SLEDAI积分。结论:血清可溶性DcR3在SLE中高表达,与SLEDAI呈正相关,治疗药物对血清DCR3浓度影响不明显,可以作为SLE诊断和评判疾病活动度的指标。
Objective: To investigate the serum level of soluble decoy receptor3 in systemic lupus erythematosus and its relationship with therapeutic agents. Methods: Fifty-one patients with SLE and 19 healthy controls were enrolled in this study. Serum soluble DcR3 concentration was measured by enzyme-linked immunosorbent assay (ELISA). SLE disease activity index (SLEDAI) was used to evaluate the activity of SLE disease. The main medication (Prednisone, cyclophosphamide, azathioprine, hydroxychloroquine, total glucosides of paeony) and serum soluble DcR3 concentration and SLEDAI. Results: The serum concentration of soluble DcR3 in SLE patients was significantly higher than that in normal controls (t = 2.42, P <0.05), and positively correlated with SLEDAI score (r = 0.373, P <0.01) Concentrations were significantly higher (P <0.05) than those in the untreated group, but significantly lower with hydroxychloroquine. In addition, with prednisone, the cyclophosphamide group had a higher SLEDAI score than the non-treated group. Conclusions: Serum soluble DcR3 is highly expressed in SLE and positively correlated with SLEDAI. The therapeutic drug has no obvious effect on serum DCR3 concentration, which can be used as an index for SLE diagnosis and assessment of disease activity.